rovelizumab
Trade name: LeukArrest
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 1996
Timeline
1990s
- Jan 1, 1996
Earliest Phase 2 Sponsor
Mechanism of action
- Integrin alpha-L/beta-2 (LFA-1)ANTAGONIST
Integrin alpha-L/beta-2 (LFA-1) antagonist
Inhibits the leukocyte¿s ability to adhere to the endothelial cell and transmigrate across the endothelial cell layer.
- Integrin alpha-M/beta-2ANTAGONIST
Integrin alpha-M/beta-2 antagonist
Inhibits the leukocyte¿s ability to adhere to the endothelial cell and transmigrate across the endothelial cell layer.
ITGAL inhibitor
- Integrin beta-2INHIBITOR
ITGB2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109224 ↗
Also known as
- hu23f2g
- leukarrest
- rovelizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| Unregistered | Phase 2 | Dec 31, 1996 | ICOS |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ICOS | For profit | 1 | 1 | 1 | 1996 |
1 organizations
Page 1 / 1